A Faster Clinical Response to Certolizumab Pegol (CZP) Treatment is Associated With Better 52-Week Outcomes in Patients With Rheumatoid Arthritis (RA)

被引：0
|
作者：
Keystone, Edward [1 ]
Curtis, Jeffrey [2 ]
Fleisehmann, Roy [3 ]
Mease, Philip [4 ]
Khanna, Dinesh [5 ]
Smolen, Joseph [6 ]
Coteur, G. [7 ]
Combe, Bernard [8 ]
机构：
[1] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[2] Univ Alabama, Birmingham, AL USA
[3] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[4] Seattle Rheumatol Associates, Seattle, WA USA
[5] Univ Calif Los Angeles, Los Angeles, CA USA
[6] Univ Vienna, Vienna, Austria
[7] UCB Pharma, Brussels, Belgium
[8] Hop Lapeyronie, F-34295 Montpellier, France
来源：
JOURNAL OF RHEUMATOLOGY | 2010年 / 37卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
181
引用
收藏
页码：1333 / 1334
页数：2
相关论文
共 50 条
  • [1] A FASTER CLINICAL RESPONSE TO CERTOLIZUMAB PEGOL (CZP) TREATMENT IS ASSOCIATED WITH BETTER 52-WEEK OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA)
    Keystone, Edward
    Curtis, Jeffery
    Fleischmann, Roy
    Mease, Philip
    Khanna, Dinesh
    Smolen, Josef
    Coteur, Geoffroy
    Combe, Bernard
    RHEUMATOLOGY, 2010, 49 : I102 - I102
  • [2] A FASTER CLINICAL RESPONSE TO CERTOLIZUMAB PEGOL TREATMENT IS ASSOCIATED WITH BETTER IMPROVEMENTS IN HOUSEHOLD PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Westhovens, Rene
    Strand, Vibeke
    Keystone, Edward C.
    Purcaru, Oana
    Khanna, Dinesh
    Smolen, Josef
    Kavanaugh, Arthur
    RHEUMATOLOGY, 2010, 49 : I97 - I98
  • [3] A Faster Clinical Response to Certolizumab Pegol Treatment is Associated With Better Improvements in Household Productivity in Patients With Rheumatoid Arthritis
    Westhovens, Rene
    Strand, Vibeke
    Keystone, Edward
    Purcaru, O.
    Khanna, Dinesh
    Smolen, Joseph
    Kavanaugh, Arthur
    JOURNAL OF RHEUMATOLOGY, 2010, 37 (06) : 1292 - 1293
  • [4] Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study
    Piercarlo Sarzi-Puttini
    Emilio Filippucci
    Silvano Adami
    Pier Luigi Meroni
    Alberto Batticciotto
    Luca Idolazzi
    Orazio De Lucia
    Pablo Talavera
    Thomas Kumke
    Walter Grassi
    Advances in Therapy, 2018, 35 : 1153 - 1168
  • [5] Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study
    Sarzi-Puttini, Piercarlo
    Filippucci, Emilio
    Adami, Silvano
    Meroni, Pier Luigi
    Batticciotto, Alberto
    Idolazzi, Luca
    De Lucia, Orazio
    Talavera, Pablo
    Kumke, Thomas
    Grassi, Walter
    ADVANCES IN THERAPY, 2018, 35 (08) : 1153 - 1168
  • [6] Safety Update on Certolizumab Pegol (CZP) in Patients with Active Rheumatoid Arthritis (RA)
    Van Vollenhoven, Ronald
    Smolen, Joseph
    Schiff, Michael
    Fleischmann, Roy
    Combe, Bernard
    Goel, Niti
    Desai, C.
    Curtis, Jeffrey
    Keystone, Edward
    JOURNAL OF RHEUMATOLOGY, 2010, 37 (06) : 1332 - 1332
  • [7] SAFETY UPDATE ON CERTOLIZUMAB PEGOL (CZP) IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)
    van Vollenhoven, Raymond
    Smolen, Josef
    Schiff, Michael
    Fleischmann, Roy
    Combe, Bernard
    Goel, Niti
    Desai, Chintu
    Curtis, Jeffery
    Keystone, Edward
    Emery, Paul
    Choy, Ernest
    RHEUMATOLOGY, 2010, 49 : I102 - I103
  • [8] REAL-WORLD UTILIZATION OF CERTOLIZUMAB PEGOL (CZP) FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN THE UNITED KINGDOM
    Bedenbaugh, A., V
    Qizilbash, N.
    Dunkel, J.
    SanJose, B.
    Mendez, I
    VALUE IN HEALTH, 2014, 17 (03) : A42 - A42
  • [9] Risk of Lymphoma in Rheumatoid Arthritis (RA) Patients Treated with Certolizumab Pegol (CZP) Compared to World and US General Populations
    Guo, Jennifer D.
    Golembesky, Amanda
    Rosario-Jansen, Theresa
    Miller, David P.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 437 - 437
  • [10] SDAI REDUCTION AT WEEK 2 PREDICT THE SDAI REMISSION AT WEEK 24 WHEN CERTOLIZUMAB PEGOL (CZP) WAS ADMINISTERED TO PATIENTS WITH RHEUMATOID ARTHRITIS
    Oryoji, K.
    Mizuki, S. -I.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1387 - 1387
12345